Group purchasing organization Novation awarded new cardiovascular contracts to a host of market leaders, effective at the beginning of 2013.
Neuravi successfully completes Series A financing
Irish medical device company Neuravi Limited successfully completed a Series A financing round for $6.5 million (€5.2 million).
Terumo Corp. (TYO:4543) warned users of its Advanced Perfusion System 1, Sarns Modular Perfusion System 8000 and Sarns Perfusion System 9000 of possible malfunctions related to the devices’ air bubble detections systems.
The company has received "multiple reports" of false alarms generated by the air bubble warning system, although it’s a "highly unlikely" malfunction.
Disappearing technology had a strong presence at this year’s EuroPCR conference in Paris, with rival device makers demonstrating the safety and efficacy of their next-generation stents.
Elixir Medical unveiled 1st-in-man clinical results for its DESolve fully bioabsorbable drug-eluting scaffold system, a stent made from a proprietary polymer and coated in novolimus. The entire stent is designed to be absorbed by the body in 1-2 years.
Consumer advocacy groups urged the U.S. House of Representatives to take a stronger hand in promoting safety in medical devices during a hearing today on the re-authorization of the medical device user fee act.
Industry officials and venture capitalists highlighted the role the med-tech sector plays in creating high-paying jobs and generating innovative, life-saving products. Consumer advocates were having none of that, chiding the user fee negotiations for putting safety on the back burner under pressure for faster review times.
Group purchasing organization Premier said it signed a raft of supply deals for a variety of medical device products.
The Charlotte-based GPO said it signed deals for endomechanical, trocar, suture and topical skin adhesives with 16 companies.
Terumo Americas Holding, the U.S. subsidiary of Japan’s Terumo Corp., acquired Onset Medical Corp., makers of access sheath technology for multiple minimally invasive applications.
Terumo is a $4 billion a year company with sales and operations in more than 160 countries, according to a press release. The value of the acquisition wasn’t made public.
CaridianBCT and Terumo Transfusion unveiled plans to join the two companies into Terumo BCT at this year’s American Assn. of Blood Banks meeting.
The two companies will operate independently until spring 2012 when they will combine to form blood component technology company Terumo BCT.